Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
BiologicsDigestive Disorder

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1551745

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1551745

Proton Pump Inhibitors (PPIs)

PUBLISHED:
PAGES: 268 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Proton Pump Inhibitors (PPIs) Market to Reach US$3.6 Billion by 2030

The global market for Proton Pump Inhibitors (PPIs) estimated at US$2.9 Billion in the year 2023, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2023-2030. Over the Counter PPIs, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Prescription PPIs segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$798.3 Million While China is Forecast to Grow at 6.2% CAGR

The Proton Pump Inhibitors (PPIs) market in the U.S. is estimated at US$798.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$749.0 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Proton Pump Inhibitors (PPIs) Market - Key Trends and Drivers Summarized

How Are Proton Pump Inhibitors (PPIs) Revolutionizing the Treatment of Acid-Related Disorders?

Proton Pump Inhibitors (PPIs) are revolutionizing the treatment of acid-related disorders by providing a highly effective means of reducing stomach acid production, thereby alleviating symptoms and promoting healing in conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. PPIs work by irreversibly inhibiting the hydrogen-potassium ATPase enzyme in the stomach lining, which is responsible for acid secretion. This mechanism allows for a more sustained and significant reduction in acid levels compared to other treatments like antacids or H2 receptor antagonists. As a result, PPIs have become the cornerstone therapy for managing chronic acid-related conditions, offering relief from symptoms such as heartburn, regurgitation, and discomfort. The effectiveness of PPIs in both symptom control and the healing of erosive esophagitis and peptic ulcers has made them one of the most commonly prescribed medications worldwide, significantly improving the quality of life for millions of patients.

What Innovations Are Enhancing the Functionality of Proton Pump Inhibitors?

Innovations in proton pump inhibitors (PPIs) are enhancing their functionality through the development of new formulations, improved drug delivery systems, and combination therapies. Recent advancements include the creation of delayed-release and extended-release formulations that allow for more consistent acid suppression over a 24-hour period, improving patient adherence and outcomes. Additionally, researchers are exploring novel drug delivery methods, such as orally disintegrating tablets (ODTs) and liquid suspensions, which offer convenience and improved absorption, particularly for patients who have difficulty swallowing pills. Another significant innovation is the development of combination therapies that pair PPIs with other medications, such as prokinetics or antibiotics, to address a broader range of gastrointestinal conditions, including those caused by Helicobacter pylori infections. These combination therapies enhance the effectiveness of treatment and provide a more comprehensive approach to managing acid-related disorders. These innovations are making PPIs more versatile, accessible, and effective, ensuring that a wider range of patients can benefit from their use.

How Do Proton Pump Inhibitors Impact Long-Term Patient Outcomes and Healthcare Costs?

Proton Pump Inhibitors (PPIs) have a profound impact on long-term patient outcomes by providing sustained relief from chronic acid-related conditions and preventing complications such as esophageal strictures, Barrett's esophagus, and gastrointestinal bleeding. By effectively managing symptoms and promoting mucosal healing, PPIs help patients maintain a better quality of life and reduce the risk of serious complications that can arise from untreated acid disorders. However, the long-term use of PPIs has raised concerns about potential side effects, such as nutrient malabsorption, increased risk of bone fractures, and susceptibility to certain infections. Despite these concerns, when used appropriately under medical supervision, the benefits of PPIs in controlling acid production and preventing complications far outweigh the risks for most patients. From a healthcare cost perspective, PPIs are generally cost-effective due to their ability to prevent hospitalizations and more invasive treatments associated with complications of acid-related disorders. The widespread availability of generic PPI formulations also makes these medications more affordable, further reducing the financial burden on both patients and healthcare systems.

What Trends Are Driving Growth in the Proton Pump Inhibitors Market?

Several trends are driving growth in the Proton Pump Inhibitors (PPIs) market, including the rising prevalence of gastrointestinal disorders, increasing awareness of acid-related conditions, and the continued demand for over-the-counter (OTC) treatment options. As lifestyles change and diets become more processed, there is a growing incidence of conditions like GERD, peptic ulcers, and dyspepsia, leading to greater demand for effective acid suppression therapies. Additionally, increased awareness of acid-related disorders and their potential complications is prompting more individuals to seek medical treatment, driving the prescription and OTC markets for PPIs. The availability of OTC PPIs has expanded access to these medications, allowing individuals to manage symptoms without the need for a prescription, which is particularly appealing to those with mild or occasional symptoms. Furthermore, ongoing research into the long-term safety and efficacy of PPIs is likely to lead to the development of newer, more targeted formulations that cater to specific patient populations, such as those with complex or refractory conditions. These trends underscore the essential role of PPIs in modern gastroenterology and their continued relevance in managing acid-related disorders in the global population.

Select Competitors (Total 37 Featured) -

  • AstraZeneca plc
  • Cadila Pharmaceuticals Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Drugwatch.com, LLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Janssen Global Services, LLC
  • Johnson & Johnson Services, Inc.
  • LUPIN Limited
  • Perrigo Company PLC
  • Pfizer Limited
  • RedHill Biopharma Ltd.
  • Sun Pharmaceutical Industries Ltd.;
Show more
Product Code: MCP24612

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Proton Pump Inhibitors (PPIs) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Gastrointestinal Disorders Driving Demand for PPIs
    • Growing Awareness of Acid Reflux and GERD Management Options
    • Rising Geriatric Population and Associated Gastrointestinal Conditions
    • Concerns Over Long-Term PPI Use and Potential Side Effects Influencing Prescribing Practices
    • Generic Drug Market Expansion Following PPI Patent Expirations
    • E-commerce and Online Pharmacies Expanding PPI Availability
    • Challenges in Over-the-Counter PPI Sales and Self-Medication Risks
    • Impact of Digital Health Technologies on Patient Management and Monitoring
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Proton Pump Inhibitors (PPIs) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Over the Counter PPIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Over the Counter PPIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Over the Counter PPIs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Prescription PPIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Prescription PPIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Prescription PPIs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • JAPAN
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • CHINA
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: China 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • EUROPE
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • FRANCE
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: France 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • GERMANY
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • INDIA
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: India 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • AFRICA
    • Proton Pump Inhibitors (PPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Proton Pump Inhibitors (PPIs) by Drug Class - Over the Counter PPIs and Prescription PPIs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Drug Class - Percentage Breakdown of Value Sales for Over the Counter PPIs and Prescription PPIs for the Years 2014, 2024 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Proton Pump Inhibitors (PPIs) by Administration Route - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Proton Pump Inhibitors (PPIs) by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!